DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2023 financial results on November 13th. The company will host a conference call on November 14th at 7:00 AM CT to provide a business update and discuss financial results. Interested parties can access the call through web access or dial-in. The webcast will be available for playback on the company's website for 12 months.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Monday, November 13^th. DiaMedica will host a live conference call on Tuesday, November 14^th at 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details:

Date:	Tuesday, November 14, 2023
Time:	7:00 AM CT / 8:00 AM ET
Web access:	https://app.webinar.net/OVpdLmgYMDE
Dial In:	(877) 550-1858
Conference ID:	1754341

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until November 21, 2023, by dialing (800) 645-7964 (US Toll Free) and entering the replay passcode: 2125#.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231106951994/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will DiaMedica Therapeutics release its third quarter 2023 financial results?

DiaMedica Therapeutics will release its third quarter 2023 financial results on November 13th.

When will DiaMedica Therapeutics host a conference call?

DiaMedica Therapeutics will host a conference call on November 14th at 7:00 AM CT.

How can interested parties access the conference call?

Interested parties can access the conference call through web access or dial-in.

Will the conference call be available for playback?

Yes, the webcast of the conference call will be available for playback on DiaMedica Therapeutics' website for 12 months.

How long will the telephonic replay of the conference call be available?

The telephonic replay of the conference call will be available until November 21, 2023.